Ipilimumab

Generic Name: Ipilimumab

Brand Names: Yervoy

Drug Type: Biotech

Chemical Formula: -

CAS Number: 477202-00-9

Unique Ingredient Identifier: 6T8C155666

Background: Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Indication: Ipilimumab is indicated in the following cancerous conditions:

Melanoma

Renal Cell Carcinoma (RCC)

Colorectal Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Esophageal Cancer

- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab

Associated Conditions: Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)

Associated Therapies: First Line Chemotherapy

Clinical Trials

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Phase 1

Completed

Conditions: Metastatic Hormone-Sensitive Prostate Cancer

Interventions: Biological: PROSTVAC-V
Biological: PROSTVAC-F
Drug: Nivolumab
Drug: Ipilimumab
Biological: Neoantigen DNA vaccine
Device: TriGrid Delivery System
Procedure: Tumor biopsy
Procedure: Peripheral blood
Procedure: Fecal samples
Procedure: Leukapheresis

First Posted Date: 2018-05-22

Last Posted Date: 2022-08-05

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 19

Registration Number: NCT03532217

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

Phase 2

Active, not recruiting

Conditions: Melanoma
Ocular Melanoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2018-05-17

Last Posted Date: 2023-04-11

Lead Sponsor: Suthee Rapisuwon

Target Recruit Count: 52

Registration Number: NCT03528408

Locations: 🇺🇸
Northwestern Univeristy Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Georgetown University, Washington, District of Columbia, United States

and more 3 locations

Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC

Phase 1

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Ipilimumab
Drug: SHR-1210

First Posted Date: 2018-05-17

Last Posted Date: 2018-05-30

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 10

Registration Number: NCT03527251

Locations: 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), GuangZhou, Guangdong, China

ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: CPI-1205
Drug: ipilimumab

First Posted Date: 2018-05-16

Last Posted Date: 2022-05-18

Lead Sponsor: Constellation Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT03525795

Locations: 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸
South Texas Oncology & Hematology, San Antonio, Texas, United States
🇺🇸
The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Phase 2

Recruiting

Conditions: Basal Cell Carcinoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Relatlimab

First Posted Date: 2018-05-11

Last Posted Date: 2024-03-22

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 57

Registration Number: NCT03521830

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

Phase 2

Recruiting

Conditions: Bladder Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Procedure: Radical cystectomy

First Posted Date: 2018-05-09

Last Posted Date: 2024-10-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 45

Registration Number: NCT03520491

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients

Phase 1

Terminated

Conditions: Non-small Cell Lung Cancer

Interventions: Radiation: hypofractionated radiotherapy
Drug: nivolumab
Drug: Ipilimumab

First Posted Date: 2018-04-26

Last Posted Date: 2023-06-15

Lead Sponsor: Assistance Publique Hopitaux De Marseille

Target Recruit Count: 6

Registration Number: NCT03509584

Locations: 🇫🇷
Assistance Publique Hôpitaux de Marseille, Marseille, France

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Phase 1

Completed

Conditions: Malignant Peritoneal Neoplasm
Malignant Retroperitoneal Neoplasm
Metastatic Cervical Carcinoma
Metastatic Endometrial Carcinoma
Metastatic Fallopian Tube Carcinoma
Metastatic Malignant Female Reproductive System Neoplasm
Metastatic Ovarian Carcinoma
Metastatic Primary Peritoneal Carcinoma
Peritoneal Carcinomatosis
Platinum-Refractory Fallopian Tube Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Biological: Ipilimumab
Biological: Nivolumab
Other: Pharmacokinetic Study

First Posted Date: 2018-04-25

Last Posted Date: 2024-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 26

Registration Number: NCT03508570

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Phase 1

Active, not recruiting

Conditions: Lymphoma
Metastatic Malignant Solid Neoplasm
Recurrent Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Copanlisib
Procedure: Echocardiography
Procedure: Magnetic Resonance Imaging
Biological: Ipilimumab
Biological: Nivolumab

First Posted Date: 2018-04-19

Last Posted Date: 2024-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 64

Registration Number: NCT03502733

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr

Phase 3

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer Metastatic

Interventions: Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2018-03-19

Last Posted Date: 2024-03-07

Lead Sponsor: Intergroupe Francophone de Cancerologie Thoracique

Target Recruit Count: 265

Registration Number: NCT03469960

Locations: 🇫🇷
Angers - CHU, Angers, France
🇫🇷
HIA Begin, Saint-Mandé, France
🇫🇷
CH de Villefranche - Pneumologie, Villefranche, France

and more 44 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy